Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of ...

Y-mAbs presented preclinical PK data for CD38-SADA at the 2025 AACR Annual Meeting, supporting its cancer treatment development. Y-mAbs Therapeutics, Inc. announced the presentation of preclinical ...